Crescita Therapeutics Inc.
CRRTF
$0.36
$0.01273.66%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 50.79% | -33.49% | 41.97% | 16.54% | -22.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.79% | -33.49% | 41.97% | 16.54% | -22.25% |
| Cost of Revenue | 28.52% | -34.95% | 128.07% | 4.30% | -13.08% |
| Gross Profit | 69.26% | -31.93% | -4.88% | 29.04% | -28.51% |
| SG&A Expenses | -3.35% | -15.57% | -1.34% | 11.26% | 0.68% |
| Depreciation & Amortization | 14.81% | -13.87% | -6.42% | -18.61% | -20.39% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.88% | -24.56% | 41.48% | 6.18% | -6.49% |
| Operating Income | 155.23% | -36.48% | -21.18% | 16.54% | -353.63% |
| Income Before Tax | 185.24% | -39.87% | -464.35% | 20.53% | -383.70% |
| Income Tax Expenses | -- | -- | -106.91% | -- | -- |
| Earnings from Continuing Operations | 185.24% | -39.87% | -4.90% | 20.53% | -223.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 185.24% | -39.87% | -4.90% | 20.53% | -223.47% |
| EBIT | 155.23% | -36.48% | -21.18% | 16.54% | -353.63% |
| EBITDA | 225.09% | -92.52% | -43.23% | 15.76% | -587.65% |
| EPS Basic | 187.64% | -43.88% | -10.91% | 15.99% | -237.86% |
| Normalized Basic EPS | 187.16% | -43.92% | -331.25% | 16.04% | -406.98% |
| EPS Diluted | 179.18% | -43.88% | 12.86% | 15.99% | -254.37% |
| Normalized Diluted EPS | 186.70% | -43.92% | -331.25% | 16.04% | -406.98% |
| Average Basic Shares Outstanding | -2.62% | -2.88% | -4.33% | -5.38% | -4.38% |
| Average Diluted Shares Outstanding | -2.09% | -2.88% | -4.33% | -5.38% | -4.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |